

Recombinant Human Interleukin-1 α (rHu IL-1 α)

Catalog No: #701011

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Description

| | |
|--------------------|--|
| Product Name | Recombinant Human Interleukin-1 α (rHu IL-1 α) |
| Brief Description | Recombinant Protein |
| Host Species | E.coli |
| Purification | > 97 % by SDS-PAGE and HPLC analyses. |
| Species Reactivity | Hu |
| Target Name | rHu IL-1 α |
| Other Names | Lymphocyte-activating factor, LAF, Leukocyte Endogenous Mediator, LEM, Endogenous Pyrogen, EP, Mononuclear Cell Factor, MCF, Hematopoietin-1 |
| Accession No. | accession:P01583 GeneID:3552 |
| Uniprot | P01583 |
| GeneID | 3552; |
| Calculated MW | Approximately 18.0 kDa, a sing |
| SDS-PAGE MW | Sterile Filtered White lyophil |
| Target Sequence | SAPFSFLSNV KYNFMRIKY EFILNDALNQ SIIRANDQYL TAAALHNLDE AVKFDMGAYK SSKDDAKITV ILRISKTLQY VTAQDEDQPV LLKEMPEIPK TITGSETNLL FFWETHGTKN YFTSVAHPNL FIATKQDYWV CLAGGPSIT DFQILENQA |
| Formulation | Lyophilized from a 0.2 μ m filtered concentrated solution in PBS, pH 7.4. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze thaw cycles. |

Background

Interleukin-1 α (IL-1 α) is a non-secreted proinflammatory cytokine produced mainly by activated macrophages, as well as neutrophils, epithelial cells, and endothelial cells. It possesses metabolic, physiological, haematopoietic activities, and plays one of the central roles in the regulation of the immune responses. Both IL-1 α and IL-1 β binds to the same receptor and has similar identical biological properties. Among various species, the amino acid sequence of mature IL-1 α is conserved 60 % to 70 % and human IL-1 has been found to be biologically active on murine cell lines. IL-1 α recently started to find effective application in cosmetic and dermatological formulations, which allow to significantly harmonizing derma architecture.

References

1. Bankers-Fulbright, J.L., K.R. Kalli, and D.J. McKean. 1996. Life Sci, 59: 61-83.
2. Dinarello, C.A. 1997. Semin Oncol, 24: S9-81-S9-93.

Note: This product is for in vitro research use only